Cargando…

Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons

PURPOSE: To evaluate the holistic cost of longer acting anti-VEGF therapy for macular degeneration when considering the associated costs of travel to the retina clinic. DESIGN: Theoretical evaluation of cost using publicly available pricing data and reimbursements at the Veterans Affairs (VA) Medica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meer, Elana A, Oh, Dennis H, Brodie, Frank L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792116/ https://www.ncbi.nlm.nih.gov/pubmed/36578665 http://dx.doi.org/10.2147/OPTH.S384995

Ejemplares similares

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
por: Park, Young Gun, et al.
Publicado: (2012)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
por: García-Quintanilla, Laura, et al.
Publicado: (2019)

Application and mechanism of anti-VEGF drugs in age-related macular degeneration
por: Song, Dawei, et al.
Publicado: (2022)

Resource Utilization and Costs of Age-Related Macular Degeneration
por: Halpern, Michael T., et al.
Publicado: (2006)

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration
por: Balikova, Irina, et al.
Publicado: (2019)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
por: Senra, Hugo, et al.
Publicado: (2016)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment
por: Oca, Ana I., et al.
Publicado: (2021)

Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
por: Ruiz-Moreno, J. M., et al.
Publicado: (2020)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration
por: Hörster, Robert, et al.
Publicado: (2010)

Therapeutic Effect of Anti-VEGF for Age-Related Macular Degeneration in the Untreated Fellow Eye
por: Isildak, Hacer, et al.
Publicado: (2018)

Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration
por: Ozdemir, Semra, et al.
Publicado: (2022)

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2018)

Cost-effectiveness of smoking cessation to prevent age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
por: Davis, R Prince, et al.
Publicado: (2010)

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration
por: Vottonen, Pasi, et al.
Publicado: (2013)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
por: Yang, Shiqi, et al.
Publicado: (2016)

Effect of anti-VEGF drugs combined with photodynamic therapy in the treatment of age-related macular degeneration
por: Dong, Yi, et al.
Publicado: (2016)

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
por: Péntek, Márta, et al.
Publicado: (2017)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
por: Miyamoto, Noriko, et al.
Publicado: (2017)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
por: Strunz, Tobias, et al.
Publicado: (2022)

Exploring the role of VEGF in Indian Age related macular degeneration
por: Sharma, Kaushal, et al.
Publicado: (2015)

Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration
por: Brown, Gary C., et al.
Publicado: (2023)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
por: Hirata, Akira, et al.
Publicado: (2017)

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2022)

Cost-Utility Analyses of Cataract Surgery in Advanced Age-Related Macular Degeneration
por: Ma, Yingyan, et al.
Publicado: (2016)

The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea
por: Ho, Ra, et al.
Publicado: (2018)

Combinatorial treatment with topical NSAIDs and anti-VEGF for age-related macular degeneration, a meta-analysis
por: Li, Songshan, et al.
Publicado: (2017)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
por: Arai, Yusuke, et al.
Publicado: (2020)

Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy
por: Reiter, Gregor S., et al.
Publicado: (2022)

Pachychoroid Neovasculopathy Disguising as Age-Related Macular Degeneration Treated by Spironolactone and Anti-VEGF Combination Therapy
por: Keidel, Leonie F., et al.
Publicado: (2021)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents
por: Zhou, Dan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hlcpqcl8dcd1gdon3m57885aeb